Finance Foggle

  Key Takeaways Sarepta Therapeutics stock plunged ~40% following a second patient death linked to its gene therapy Elevidys . FDA may pull Elevidys off the market as safety concerns mount; shipments halted for non-ambulatory patients . Therapy initially approved controversially in 2023 for ages 4-5, later expanded amid efficacy debates . Year-to-date stock loss exceeds 87%, erasing billions in market value . Duchenne muscular dystrophy patients face renewed uncertainty as treatment risks outweigh benefits for some . The Bloodbath on Nasdaq Sarepta Therapeutics stock cratered 40% in premarket trading June 16, 2025. It opened at $13.60, a far cry from its 52-week high of $150.48 . The collapse wasn't a surprise to those watching the ticker. Shares had been dying a slow death all year. By July, the year-to-date loss hit 87.5% . Shareholders stared at ruins. Trading volume exploded to 60 million shares. Average volume is 5.9 million . The market cap vaporized, $1.336 billion intraday....